Clinical Trials Sponsored by Apros Therapeutics, Inc

Total 2962 results

Apros Therapeutics, Inc

Completed

A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions

Advanced Colorectal Carcinoma

United States
Akros Pharma Inc.

Withdrawn

Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension (RELIEF-PAH)

Pulmonary Arterial Hypertension
Akros Pharma Inc.

Completed

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

Anemia of Chronic Kidney Disease

United States
Akros Pharma Inc.

Completed

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

Anemia of Chronic Kidney Disease

United States
Akros Pharma Inc.

Completed

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

Anemia in Chronic Kidney Disease

United States
Akros Pharma Inc.

Terminated

Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

Type II Diabetes Mellitus

United States
Akros Pharma Inc.

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Akros Pharma Inc.

Completed

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

Diabetes Mellitus

United States
Akros Pharma Inc.

Completed

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Dyslipidemia

United States
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Type II Diabetes Mellitus

United States, Russian Federation, Czech Republic, Hungary, Netherlands
Akros Pharma Inc.

Completed

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

Healthy

United States
Akros Pharma Inc.

Terminated

Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects

Healthy

United States
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

Dyslipidemia

Netherlands
Akros Pharma Inc.

Completed

Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

Type II Hyperlipidemia

Netherlands
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

Dyslipidemia

Netherlands
Akros Pharma Inc.

Completed

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)

Skin Diseases | Psoriasis | Plaque Psoriasis

United States, Canada, Poland
Akros Pharma Inc.

Terminated

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)

Skin Diseases | Plaque Psoriasis

United States, Canada
Akros Pharma Inc.

Completed

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis (MOVE-RA)

Rheumatoid Arthritis

Ukraine, United States, Argentina, Bulgaria, Romania, Peru, Russian Federation, Mexico, Colombia, Poland
Akros Pharma Inc.

Completed

Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects

Skin Diseases | Psoriasis | Plaque Psoriasis

Canada
Akros Pharma Inc.

Terminated

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

Diabetes Mellitus

United States
Akros Pharma Inc.

Completed

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

Anemia of Chronic Kidney Disease

United States
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Akros Pharma Inc.

Completed

Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Dyslipidemia

United States
Akros Pharma Inc.

Completed

Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects

Hepatitis C Virus Infection, Response to Therapy of

Puerto Rico
Akros Pharma Inc.
ICON Clinical Research

Recruiting

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction (POWER-HF)

Chronic Heart Failure

United States
BlackThorn Therapeutics, Inc.
Neumora Therapeutics, Inc.

Completed

Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo

Major Depressive Disorder

United States
Sirion Therapeutics, Inc.
ReVision Therapeutics, Inc.

Completed

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Geographic Atrophy | Dry Age Related Macular Degeneration
Therapeutics, Inc.

Completed

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

Tinea Pedis

United States, Puerto Rico
Therapeutics, Inc.

Completed

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

Plaque Psoriasis

United States, Georgia, Ukraine
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (305)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

Tinea Pedis | Tinea Cruris

United States
Therapeutics, Inc.

Completed

A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis

Scalp Psoriasis

United States
Therapeutics, Inc.

Completed

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Acne Vulgaris

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

Plaque Psoriasis

United States
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With IgA Nephropathy (ALIGN)

Immunoglobulin A Nephropathy | IgA Nephropathy

United States, Spain, Canada, Taiwan, Hong Kong, China, New Zealand, United Kingdom, Korea, Republic of, Australia, Germany, France, India, Japan, Czechia, Argentina, Italy, Colombia, Ireland, Brazil, Poland, Portugal
Millendo Therapeutics US, Inc.

Terminated

Nevanimibe HCl for the Treatment of Classic CAH

Congenital Adrenal Hyperplasia

Spain, Israel, France, Brazil, Czechia
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

Diabetic Kidney Disease | Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy | IgA Nephropathy | Diabetic Nephropathy Type 2 | Alport Syndrome

United States, Spain, Korea, Republic of, Australia, Italy, United Kingdom
Millendo Therapeutics US, Inc.

Terminated

A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

Cushing Syndrome

United States, United Kingdom
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Cascadian Therapeutics Inc.
Celldex Therapeutics

Completed

Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer

Advanced Breast Carcinoma | Advanced Ovarian Carcinoma

United States

3

Subscribe